Ondansetron

Overview

Ondansetron, sold under the brand name Zofran among others, is a medication used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, migraines, or surgery. It is also effective for treating gastroenteritis. It can be given orally (by mouth), intramuscularly (injection into a muscle), or intravenously (injection into a vein).[1][2][3] WP

Common side effects include diarrhea, constipation, headache, sleepiness, and itchiness. Serious side effects include QT prolongation and severe allergic reaction. It appears to be safe during pregnancy but has not been well studied in this group. It is a serotonin 5-HT₃ receptor antagonist. It does not have any effect on dopamine receptors or muscarinic acetylcholine receptor and therefore does not cause akathisia.[1][4] WP

Ondansetron was patented in 1984 and approved for medical use in 1990. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 53rd most commonly prescribed medication in the United States, with more than 12 million prescriptions.[1][5–8] WP

Uses, dosage and effects

Medical uses

Ondansetron is indicated for the prevention of chemotherapy-induced nausea and vomiting and postoperative nausea and vomiting.[9][10] WP

Pregnancy

Ondansetron is used off-label to treat morning sickness and hyperemesis gravidarum of pregnancy. It is typically used after other antiemetic drugs have failed.[11] WP

A large multi-center cohort study found no association between ondansetron exposure and fetal risk compared to other antiemetics.[12] WP

Cyclic vomiting syndrome

Ondansetron is one of several antiemetics used during the vomiting phase of cyclic vomiting syndrome.[13] WP

Gastroenteritis

Trials in emergency department settings support the use of ondansetron to abort vomiting episodes associated with gastroenteritis and dehydration. A randomized controlled trial using a single dose of oral ondansetron in children with presumably viral gastroenteritis found it to be highly effective in stopping vomiting and increasing the effectiveness of oral rehydration therapy, thereby significantly increasing patient satisfaction. Only 16 of the 123 children treated with ondansetron vomited in the following 6 hours. A retrospective review found that ondansetron was used commonly for vomiting due to gastroenteritis, being administered in over 58% of cases. Its use reduced hospital admissions, but was also associated with higher rates of return visits to the emergency department. Furthermore, people who had initially received ondansetron were more likely to be admitted on the return visit than people who had not received the drug. However, this effect may simply be due to the agent being used more frequently in people who present with more severe illness. Its use was not found to mask serious diagnoses.[14][15][16] WP

Irritable bowel syndrome (IBS)

In a study of patients diagnosed as having IBS with diarrhea (IBS-D), ondansetron showed statistically significant effects on stool consistency, frequency, urgency and bloating, but not on pain scores. This was confirmed in a later trial and meta-analysis and is included in international guidelines.[17][18][19] WP

Risks and side effects

Adverse effects

Headaches are the most common adverse effect. A review of use for post-operative nausea and vomiting found that for every 36 people treated, one would experience headache, which could be severe.[9][20] WP

Constipation, diarrhea, and dizziness are other commonly reported side effects. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.[1] WP

QT prolongation

Use of ondansetron has been associated with prolongation of the QT interval, which can lead to a potentially fatal heart rhythm known as torsades de pointes. Although this may happen in any person with any formulation, the risk is most salient with the injectable (intravenous) form of the drug and increases with dose. The risk is also higher in people taking other medicines that prolong the QT interval, as well as in people with congenital long QT syndrome, congestive heart failure, and/or bradyarrhythmias. As such, single doses of injectable ondansetron should not exceed 16 mg at one time. (Oral dosing recommendations remain intact, including the recommendation of a single 24 mg oral dose when indicated.) Electrolyte imbalances should be corrected before the use of injectable ondansetron. People are cautioned to seek immediate medical care if symptoms such as irregular heartbeat or palpitations, shortness of breath, dizziness, or fainting occur while taking ondansetron.[21] WP

Overdose

No specific treatment is available for ondansetron overdose; people are managed with supportive measures. An antidote to ondansetron is not known.[9] WP

Serotonin syndrome

In 2012, the World Health Organization (WHO), US Food and Drug Administration (FDA), and Health Canada (HC) in 2014 released reports and added a boxed warning, that stated use of ondansetron in conjunction with serotonergic drugs (SSRIs, SNRIs, MAOIs, and TCAs) had been linked to rare cases of serotonin syndrome. Although some members of the scientific and medical community believe these reports were released without substantive evidential foundation, and that the studies cited by the FDA, WHO, and HC were flawed. They claim there is no clear and convincing evidence that ondansetron is capable of causing serotonin syndrome, nor any well documented cases where serotonin syndrome could be definitively linked to ondansetron use with a serotonergic drug, leading to needless avoidance of ondansetron for patients taking SSRIs, SNRIs and tricyclics.[22–25] WP

Pharmacology

Pharmacodynamics

Ondansetron is a highly selective serotonin 5-HT₃ receptor antagonist, with low affinity for dopamine receptors. The 5-HT₃ receptors are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema in the medulla. Serotonin is released by the enterochromaffin cells of the small intestine in response to chemotherapeutic agents and may stimulate vagal afferents (via 5-HT₃ receptors) to initiate the vomiting reflex. It is thought that ondansetron's antiemetic action is mediated mostly via antagonism of vagal afferents with a minor contribution from antagonism of central receptors. The R– and S–ondansetron isomers have similar potency as serotonin antagonists when tested on ex vivo rat vagus nerve. However, the R–ondansetron enantiomer was 7.9 times more potent as an antagonist of serotonin and 2-methyl-5-hydroxytryptamine (2-methylserotonin) when tested on the longitudinal smooth muscle from guinea pig ileum. However, the guinea pig ileum test was likely not as faithful as a test of 5-HT₃ receptor antagonism, because ondansetron only partially blocked the effect of serotonin, while it completely blocked the effect of 2-methylserotonin.[26][27] WP

Ondansetron shows human ether-à-go-go-related gene (hERG) inhibition, which is thought to underlie its QT prolongation.[28][29] WP

Pharmacokinetics

Onset of action is about 30 minutes after administration, with effects peaking at about two hours after oral administration or one hour after oral soluble film administration. Ondansetron may have a degree of peripheral selectivity due to binding to P-glycoprotein and efflux out of the brain at the blood–brain barrier. Ondansetron is marketed as a racemic mixture of R–(–)–ondansetron and S–(+)–ondansetron, and the two enantiomers have significantly different kinetics. In rats given 2 mg/kg intravenous doses of each enantiomer separately, R–(–)–ondansetron was found to have a 37% longer half-life (P < 0.05) and an 87% higher area-under-curve or AUC (P < 0.01) compared to S–(+)–ondansetron, indicating that the R enantiomer is metabolized more slowly. The chiral carbon in ondansetron is adjacent to a carbonyl group, so keto-enol tautomerism could theoretically lead to interconversion between the two enantiomers under physiologic conditions, if the hydrogen on the chiral carbon were removed and then replaced with opposite chirality. An experiment in rats given each enantiomer separately showed no evidence of this interconversion, the chirality was stable in vivo. A study of 141 human patients given 4 or 8 mg of intravenous ondansetron for the prevention of post-operative nausea and vomiting also found that R and S–ondansetron have different pharmacokinetic properties. Each patient was classified according to their genotype for the liver enzymes CYP2D6 and CYP3A5, and they were put on a spectrum between poor metabolizers (slow) and ultra metabolizers (fast). CYP2D6 was found to be more important for the elimination of S–ondansetron, whereas CYP3A5 genotype had no impact on S–ondansetron plasma levels, measured 3 hours after drug administration. CYP3A5 was more important for R–ondansetron clearance, and CYP2D6 genotype had no consistent effect on plasma levels of R–ondansetron at 3 hours.[30–35] WP

Research

Research

Ondansetron may be useful in the treatment of nausea and vomiting that can sometimes be induced by certain serotonergic psychedelics.[36][37] WP

History

History

Ondansetron (marketed under the brand name Zofran) was developed in the mid-1980s by GlaxoSmithKline in London. It was granted U.S. patent protection in September 1987, received a use patent June 1988, and was approved by the U.S. Food and Drug Administration (FDA) in January 1991. It was granted another divisional patent in November 1996. Finally, owing to GlaxoSmithKline's research on pediatric use, ondansetron's patent protection was extended until December 2006. By this final year of its patent (2006), Zofran had become the 20th highest-selling brand-name drug in the United States, with sales of US$1.3 billion in the first 9 months of 2006 (80% from the US). The first generic versions were approved by the U.S. FDA in December 2006, with marketing approval granted to Teva Pharmaceuticals USA and SICOR Pharmaceuticals.[38–43] WP

In December 2012, the FDA announced that the 32 mg, single intravenous (IV) dose of ondansetron was being withdrawn from U.S. market because of the potential for serious cardiac issues from prolonged QT interval.[44] WP

In 2018, University of São Paulo and Biolab were granted a patent for an orodispersible form of the drug.[45] WP

Legal status

Publication bias

In 1997, ondansetron was the subject of a meta-analysis case study. Researchers examined 84 trials, with 11,980 people receiving ondansetron, published between 1991 and September 1996. Intravenous ondansetron 4 mg versus placebo was investigated in 16 reports and three further reports which had been duplicated a total of six times. The number needed to treat (NNT) to prevent vomiting within 24 hours was 9.5, with 95% confidence interval 6.9 to 15, in the 16 nonduplicated reports. In the three duplicated reports, the NNT was significantly lower at 3.9 (3.3 to 4.8). When all 25 reports were combined, the apparent NNT improved to 4.9 (4.4 to 5.6). Inclusion of duplicate reports led to a 23% overestimation of ondansetron's antiemetic efficacy.[46] WP

In addition, the authors found the covert duplication of reports on ondansetron was not easy to detect, because of lack of cross-referencing between papers, and reports containing duplicate findings were cited in eight reviews of the drug. Their analysis was a subject of an editorial in the Journal of the American Medical Association in 1999.[46][47] WP

Availability

Ondansetron is a generic medication and is available in many countries under many brand names.[48] WP

Chemistry

Formula

C18H19N3O PC

CAS number

99614-02-5 PC

Molar mass (g/mol)

293.4 PC

IUPAC name (computed by PubChem)

9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one PC

SMILES

CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C PC

InChIKey

FELGMEQIXOGIFQ-UHFFFAOYSA-N PC

PubChem CID

4595

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Ondansetron Hydrochloride
2. Journal / agency Schnadower D, Finkelstein Y, Freedman SB. Ondansetron and probiotics in the management of pediatric acute gastroenteritis in developed countries. Current Opinion in Gastroenterology. January 2015. doi:10.1097/mog.0000000000000132 · PMID 25333367
3. Journal / agency Freedman SB, Ali S, Oleszczuk M, Gouin S, Hartling L. Treatment of acute gastroenteritis in children: an overview of systematic reviews of interventions commonly used in developed countries. Evidence-Based Child Health. July 2013. doi:10.1002/ebch.1932 · PMID 23877938
4. Other Peterson's principles of oral and maxillofacial surgery. 2012
5. Other FischerJ, Ganellin CR. Analogue-based Drug Discovery. 2006
6. Other World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). 2023
7. Other Top 300 of 2023
8. Other Ondansetron Drug Usage Statistics, United States, 2014 - 2023
9. Journal / agency Zofran- ondansetron hydrochloride tablet, film coated. 24 June 2020
10. Journal / agency Ondansetron hydrochloride injection. 19 October 2022
11. Other Smith JA, Refuerzo JS, Ramin SM. Treatment and outcome of nausea and vomiting of pregnancy
12. Journal / agency Dormuth CR, Winquist B, Fisher A, et al. Comparison of Pregnancy Outcomes of Patients Treated With Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort. JAMA Netw Open. April 2021. doi:10.1001/jamanetworkopen.2021.5329 · PMID 33890993 · PMC8065380
13. Journal / agency Abell TL, Adams KA, Boles RG, Bousvaros A, Chong SK, Fleisher DR, Hasler WL, Hyman PE, Issenman RM, Li BU, Linder SL, Mayer EA, McCallum RW, Olden K, Parkman HP, Rudolph CD, Taché Y, Tarbell S, Vakil N. Cyclic vomiting syndrome in adults. Neurogastroenterology and Motility. April 2008. doi:10.1111/j.1365-2982.2008.01113.x · PMID 18371009
14. Journal / agency Freedman SB, Adler M, Seshadri R, Powell EC. Oral ondansetron for gastroenteritis in a pediatric emergency department. The New England Journal of Medicine. April 2006. doi:10.1056/NEJMoa055119 · PMID 16625009
15. Journal / agency Hanif H, Jaffry H, Jamshed F, Amreek F, Kumar N, Hussain W, Rizwan A. Oral Ondansetron versus Domperidone for Acute Gastroenteritis Associated Vomiting in Young Children. Cureus. September 2019. doi:10.7759/cureus.5639 · PMID 31700742 · PMC6822884
16. Journal / agency Sturm JJ, Hirsh DA, Schweickert A, Massey R, Simon HK. Ondansetron use in the pediatric emergency department and effects on hospitalization and return rates: are we masking alternative diagnoses?. Annals of Emergency Medicine. May 2010. doi:10.1016/j.annemergmed.2009.11.011 · PMID 20031265
17. Journal / agency Garsed K, Chernova J, Hastings M, Lam C, Marciani L, Singh G, Henry A, Hall I, Whorwell P, Spiller R. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. October 2014. doi:10.1136/gutjnl-2013-305989 · PMID 24334242 · PMC4173656
18. Journal / agency Gunn D, Topan R, Barnard L, Fried R, Holloway I, Brindle R, Corsetti M, Scott M, Farmer A, Kapur K, Sanders D, Eugenicos M, Trudgill N, Whorwell P, Mclaughlin J, Akbar A, Houghton L, Dinning PG, Aziz Q, Ford AC, Farrin AJ, Spiller R. Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial. Alimentary Pharmacology & Therapeutics. June 2023. doi:10.1111/apt.17426 · PMID 36866724
19. Journal / agency Savarino E, Zingone F, Barberio B, Marasco G, Akyuz F, Akpinar H, Barboi O, Bodini G, Bor S, Chiarioni G, Cristian G, Corsetti M, Di Sabatino A, Dimitriu AM, Drug V, Dumitrascu DL, Ford AC, Hauser G, Nakov R, Patel N, Pohl D, Sfarti C, Serra J, Simrén M, Suciu A, Tack J, Toruner M, Walters J, Cremon C, Barbara G. Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. United European Gastroenterology Journal. July 2022. doi:10.1002/ueg2.12259 · PMID 35695704 · PMC9278595
20. Journal / agency Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. Anesthesiology. December 1997. doi:10.1097/00000542-199712000-00004 · PMID 9416710
21. Journal / agency FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran)
22. Journal / agency WHO-PQ RECOMMENDED SUMMARY OF PRODUCT CHARACTERISTICS
23. Journal / agency Prescribing Information for ZOFRAN TABLETS, ZOFRAN ODT, and ZOFRAN ORAL SOLUTION
24. Other Consumer Information for: PMS-ONDANSETRON ODT
25. Journal / agency Rojas-Fernandez CH. Can 5-HT₃ Antagonists Really Contribute to Serotonin Toxicity? A Call for Clarity and Pharmacological Law and Order. Drugs - Real World Outcomes. December 2014. doi:10.1007/s40801-014-0004-3 · PMID 27747475 · PMC4883185
26. Journal / agency Browning KN. Role of central vagal 5-HT3 receptors in gastrointestinal physiology and pathophysiology. Frontiers in Neuroscience. October 2015. doi:10.3389/fnins.2015.00413 · PMID 26578870 · PMC4625078
27. Journal / agency Butler A, Hill JM, Ireland SJ, Jordan CC, Tyers MB. Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. British Journal of Pharmacology. June 1988. doi:10.1111/j.1476-5381.1988.tb11542.x · PMID 2969267 · PMC1854010
28. Journal / agency Al-Ramadan A, Kidess GG, Bahar AR, Bahar Y, Hazique M, Alraies M. Morbidity and Mortality of Ondansetron in Patients with Non-congenital Long QT Syndrome: A Review Article. Cardiovasc Drugs Ther. June 2026. doi:10.1007/s10557-025-07766-2 · PMID 40856942
29. Journal / agency Kuryshev YA, Brown AM, Wang L, Benedict CR, Rampe D. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther. November 2000. doi:10.1016/S0022-3565(24)38946-3 · PMID 11046096
30. Other Ondansetron: Dosage, Mechanism/Onset of Action, Half-Life
31. Journal / agency Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation. June 1996. doi:10.1172/JCI118699 · PMID 8647944 · PMC507337
32. Journal / agency Kwan C, Bédard D, Frouni I, Gaudette F, Beaudry F, Hamadjida A, Huot P. Pharmacokinetic profile of the selective 5-HT3 receptor antagonist ondansetron in the rat: an original study and a minireview of the behavioural pharmacological literature in the rat. Canadian Journal of Physiology and Pharmacology. July 2020. doi:10.1139/cjpp-2019-0551 · PMID 32017606
33. Journal / agency Scott JA, Wood M, Flood P. The pronociceptive effect of ondansetron in the setting of P-glycoprotein inhibition. Anesthesia & Analgesia. September 2006. doi:10.1213/01.ane.0000228861.80314.22 · PMID 16931690
34. Journal / agency Duan M, Zhao Q, Zhong D, Yuan Y. Pharmacokinetics of R-(-)ondansetron compared with that of S-(-)ondansetron in rats using an LC-MS/MS method. Biomedical Chromatography. March 2019. doi:10.1002/bmc.4426 · PMID 30408206
35. Journal / agency Stamer UM, Lee EH, Rauers NI, Zhang L, Kleine-Brueggeney M, Fimmers R, Stuber F, Musshoff F. CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care. Anesthesia and Analgesia. July 2011. doi:10.1213/ANE.0b013e31821d01bc · PMID 21596874
36. Journal / agency Rossi GN, Hallak JE, Bouso Saiz JC, Dos Santos RG. Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. Expert Opinion on Drug Safety. June 2022. doi:10.1080/14740338.2022.2066650 · PMID 35426754
37. Journal / agency Glennon RA, Dukat M. Quipazine: Classical hallucinogen? Novel psychedelic?. Australian Journal of Chemistry. May 2023. doi:10.1071/CH22256
38. Other 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
39. Other Method for treating nausea and vomiting
40. Other Medicaments for the treatment of nausea and vomiting
41. Journal / agency One Year Post-Pediatric Exclusivity Post-marketing Adverse Event Review: Drug Use Data Zofran. 7 March 2006
42. Other Generics Firms Line Up to Enter Zofran Market
43. Journal / agency FDA Approves First Generic Ondansetron Tablets, Orally Disintegrating Tablets and Oral Solution. 17 December 2006
44. Journal / agency FDA Drug Safety Communication: Updated information on 32 mg intravenous ondansetron (Zofran) dose and pre-mixed ondansetron products
45. Other Sabia que um remédio para enjoo traz 90% dos royalties que a USP recebe? - Agência USP de Inovação
46. Journal / agency Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ. Impact of covert duplicate publication on meta-analysis: a case study. BMJ. September 1997. doi:10.1136/bmj.315.7109.635 · PMID 9310564 · PMC2127450
47. Journal / agency Rennie D. Fair conduct and fair reporting of clinical trials. JAMA. November 1999. doi:10.1001/jama.282.18.1766 · PMID 10568651
48. Other Ondansetron international. 2 September 2020

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.